FOR VA PROVIDERS: sTMS IS NOW A COVERED VA BENEFIT
Veterans may be more likely to experience migraine attacks and headaches than civilians.
In 2018, Congress mandated that the VA establish the Headache Centers of Excellence (HCOE) to address the growing need for improved care within the VA Healthcare System. The care of migraine has now expanded through the VA using the care guidelines established by the HCOE.
The use of non-medication neuromodulation is included in those care guidelines and is a covered VA benefit.
sTMS is the only non-invasive, patient-administered central neuromodulation device that directly targets and signals the brain to quiet the hyperactive nerves thought to be the source of migraine. This smart technology includes Remote Therapeutic Monitoring that allows you to monitor patient progress.
How to Prescribe sTMS Migraine Therapy for your VA Patients
Prosthetics:
Available on the FSS schedule
eNeura Customer
Care drop-ships
the sTMS
directly to the
patient
Company Information
Email: customercare@eneura.com
Fax: 561.316.0224
Phone: 833.499.9300
Aruene Corporation
225 Southern Blvd Suite 202
West Palm Beach FL 33405
Ordering Information
sTMS Migraine Therapy Activation
Item # 16140-0020-13-3
Three (3) months activation of sTMS Migraine Therapy
Item # 16140-0020-13-12
Twelve (12) months activation of sTMS Migraine Therapy
SDVOSB distributor: Recon Spine LLC DBA Recon Supply
Email: sales@recon-supply.com
Phone: 314-610-2334
Fax: 636-206-5220
UEI: VM5WVJD8U7N3
FSS Number: 36F79720D0009
Treat migraine attacks + Prevent Future Attacks
sTMS is the only FDA cleared central neuromodulation therapy for both acute and preventive treatment in patients 12 years and older.
Effective
In a study of people who treated with sTMS, 46% reported a 50% reduction of migraine days at 12 weeks. In another study, more people using sTMS experienced pain freedom and freedom from bothersome migraine symptoms at 2 hours versus placebo. These benefits were sustained through 48 hours.
Safe
The most commonly reported device related adverse events: lightheadedness (3.7%), tingling (3.2%) and tinnitus (3.2%), these typically resolve immediately after treatment. There have been no serious adverse events reported.
sTMS is contraindicated for patients with conductive metal implants in the head and neck, excluding dental work. MRI Protocols may be a reasonable guide in assessing the safety of sTMS in patients with metal in the head and neck.